Table of Contents
Scholarly Research Exchange
Volume 2009, Article ID 641360, 4 pages
http://dx.doi.org/10.3814/2009/641360
Clinical Study

IgA Anticardiolipin in Patients with Gastroenteric Tumor

1Physiopathology Section, Department of Clinical and Experimental Medicine, Policlinico Monteluce, Via Brunamonti, 06100 Perugia, Italy
2Chemo-Clinical Analysis Laboratory, Silvestrini Hospital, 06100 Perugia, Italy

Received 22 July 2008; Revised 18 November 2008; Accepted 8 January 2009

Copyright © 2009 Ilaria Bernardini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Recently the presence of antiphospholipid antibodies in patients with cancer has been demonstrated, suggesting an involvement of autoimmune response in neoplastic conditions. The presence of antiphospholipid antibodies in tumor disease is highly correlated with the risk of developing thrombotic complications, which represents a significant cause of morbidity and mortality in cancer patients. Interestingly, it has been highlighted that high levels of IgM and IgG anticardiolipin antibodies are more often produced in patients with gastroenteric tumor than in patients with either ovarian or breast tumor. Thus far, there are no data looking into the role or measurements of IgA in patients with solid cancer. Our preliminary results, in this study, demonstrate that testing only for IgG and IgM anticardiolipin antibodies may increase the incidence of false positive because 44% who were IgA positive and IgG and IgM negative had high titres of CA19.9 and CEA. We suggest that taking into account the role of IgA could substantially improve the detection of antiphospholipids antibodies in subjects with solid cancer, and this detection may allow us for better prevention and management of thrombotic complications in these patients.